Levodex

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levodex

Quick Facts

Property Description
Active ingredient Levofloxacin
Form Tablet, Solution (Oral, IV, Ophthalmic)
Pharmacological class Fluoroquinolone Antibiotic
Common use Systemic and localized bacterial infections
Origin Synthetic compound

What Type of Medicine is Levodex and What is its Active Component?

Levodex is a prescription antibacterial drug that belongs to the Fluoroquinolone Antibiotic class. Its identity is defined by the sole active ingredient, Levofloxacin (INN), a synthetic compound that is the purified L-isomer, or the S-(-)-isomer of Ofloxacin. Levofloxacin exhibits broad activity against various Gram-negative and Gram-positive organisms.

As a fluoroquinolone, this medication is indicated for use in adult patients. This confirms that the medicine is an officially recognized tool used by healthcare professionals to manage specific types of infections.

Available Pharmaceutical Preparations and General Purpose

The core active ingredient Levofloxacin is prepared in various dosage form(s) to ensure effective distribution throughout the body or precise local application, a characteristic valued in clinical settings. These preparations include the tablet and oral solution for systemic oral delivery, the injectable solution for intravenous infusion, and the ophthalmic solution for topical use in the eye. This variety allows the single-component product to be adapted to different infection sites, such as treating an infection affecting the lungs or resolving a localized bacterial conjunctivitis.

Levofloxacin works to kill bacteria by interfering with their DNA replication process. This mechanism of effect highlights the drug's purpose: to serve as a potent broad-spectrum antimicrobial agent, actively eliminating harmful bacterial organisms to resolve both systemic and localized bacterial infections.

Regulatory References

  1. Levofloxacin Drug Information from MedlinePlus
  2. NIH MedlinePlus

What side effects are possible with Levodex?

Possible Side Effects and Safety Information

Levodex (Levofloxacin), a fluoroquinolone antibiotic, is associated with a range of officially documented adverse reactions that vary in frequency and severity, according to government regulatory documents (e.g., FDA, EMA SmPC).


Frequency and System-Organ Classes

The most common side effects listed in regulatory labeling include gastrointestinal issues such as nausea and diarrhea, as well as headache, insomnia, and dizziness. Less frequent, or uncommon, reactions include anxiety, vomiting, and skin rash. Adverse effects are officially classified across various system-organ classes, including the Musculoskeletal, Nervous System, Gastrointestinal, and Cardiac systems.


Serious Adverse Reactions and Safety Constraints

The regulatory safety profile highlights the risk of serious and potentially irreversible adverse reactions. These include effects on the tendons (e.g., tendinitis and tendon rupture), the peripheral nerves (peripheral neuropathy), and the central nervous system (e.g., seizures or severe headaches). These reactions may occur as early as 48 hours after starting treatment or up to several months after discontinuation.

Specific safety considerations exist for certain groups. Older adults (age ge 60) and patients concurrently taking corticosteroids have an officially documented increased risk of tendon damage. The medicine's use is formally restricted for certain common infections (e.g., uncomplicated urinary tract infection) when alternative treatments are available, reflecting the seriousness of the documented risks.

Overdose and Emergency Response

Overdose and when to seek help

Documented Overdose Profile

An overdose is defined by the severe, potentially fatal risk of liver injury (hepatotoxicity). This serious consequence can occur following a single massive ingestion or from repeated excessive doses taken over a period of days (chronic supratherapeutic ingestion).

Initial signs of overdose, such as nausea, vomiting, sweating, and general discomfort, may be delayed by 12 or more hours following the acute ingestion. Because these early symptoms are often mild or even absent, they do not reliably indicate the severity of the potential liver damage.

When Immediate Medical Help Is Required

Immediate emergency medical attention must be sought if an overdose is suspected, regardless of whether or not initial symptoms are present. Waiting for symptoms of liver damage to appear significantly reduces the effectiveness of life-saving interventions.

Physiological systems primarily affected include the hepatic (liver) system, with potential progression to acute liver failure (ALF) and subsequent multi-organ effects. Prompt medical action is essential to initiate administration of the life-saving antidote, N-acetylcysteine, which is most effective when given within eight hours of ingestion. Patients with risk factors such as chronic alcoholism or malnutrition face an increased risk of severe toxicity.

Therapeutic Uses of Levodex

What Levodex Treats: Main Uses and Benefits

Levodex (Levofloxacin) is commonly used for managing bacterial infections and to help address systemic or localized bacterial infections across multiple body systems, and is applied in addressing symptoms during acute episodes. It is considered relevant across several domains where short-term symptomatic assistance is appropriate.


This medication helps address symptom clusters that may become intense or disruptive in conditions such as pneumonia, complicated urinary tract infections (UTIs), acute pyelonephritis, acute bacterial rhinosinusitis, and complicated skin and soft tissue infections. Its application assists with managing associated symptoms related to physical discomfort and systemic imbalance, including high fever, painful urination, and localized inflammation. This may help improve day-to-day comfort during symptomatic periods.

The medication is also commonly used for post-exposure prevention of severe biothreats like inhalational anthrax and plague, and may be part of symptomatic and prophylactic management.

Quick Fact: Support for Symptoms of Infection-Related Discomfort


Key Therapeutic Applications

Levodex is applied across therapeutic domains involving heightened discomfort, including the lower respiratory tract, the entire urinary tract, the skin and soft tissues, and the prostate (chronic bacterial prostatitis). Its use is relevant for easing challenging manifestations and may assist with maintaining functional stability during the infectious phase.

Regulatory References

  1. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7fa92e42-2831-4073-b9b2-3045dee74a74

Eligibility and Restrictions for Use

The eligibility for Levodex (dexamethasone and levofloxacin ophthalmic solution) is strictly defined by regulatory documents, specifying populations who are allowed to use the medicine, who must not, and who requires restricted use.

Populations Excluded from Use

Classification Regulatory Status
Absolute Contraindications Patients with a known hypersensitivity to levofloxacin, other quinolones, dexamethasone, or any component of the formulation. Patients with active viral diseases (e.g., Herpes simplex keratitis, vaccinia, varicella) or untreated fungal/mycobacterial infections of the eye.

Age and Physiological Status Rules

Classification Regulatory Status
Age Eligibility Use is authorized for adults (ge 18 years). Safety and effectiveness are not established in the pediatric population.
Pregnancy and Lactation Use is not recommended in pregnancy, and caution is advised during breastfeeding due to the components possibly passing into human milk.

Conditional Eligibility

Use requires special caution and monitoring in patients with pre-existing conditions like glaucoma or diabetes mellitus due to the corticosteroid component. The medicine is intended solely for patients receiving therapy associated with the approved indication.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies several clinically significant interactions with Levodex that require specific management or avoidance. These interactions are categorized based on their mechanism and resulting clinical constraint.


Pharmacokinetic and Absorption Constraints

Co-administration with products containing polyvalent cations (such as aluminum, magnesium, iron, zinc, or calcium) or sucralfate significantly reduces Levodex's oral absorption through chelation. To mitigate this effect, administration of Levodex must be separated from these products by at least 4 hours.

Levodex is documented as an inhibitor of drug-metabolizing enzymes and transporters, including CYP3A4 and P-glycoprotein (P-gp). This can increase the plasma concentration of co-administered drugs that are sensitive substrates for these pathways. Consequently, co-administration with certain sensitive CYP3A4 substrates is contraindicated, and dose adjustment or close monitoring is required for others, such as atorvastatin or metformin.


Pharmacodynamic Risks

Due to the risk of serious ventricular arrhythmias, including Torsades de Pointes, co-administration with other medicines known to prolong the QT interval is contraindicated.

Concurrent use with insulin or oral hypoglycemic agents may disturb blood glucose control, including the risk of both hypoglycemia and hyperglycemia. Patients co-administering these medicines require close blood glucose monitoring.

Certain foods, such as soybean-based infant formula, are documented to interfere with absorption and should not be administered simultaneously with Levodex.

Mechanism of Action

How Levodex Works

The mechanism of action for Levodex (Levofloxacin) is defined by its ability to execute a targeted and destructive effect on fundamental microbial processes, resulting in the bactericidal action that causes the death of susceptible organisms. The drug's influence operates through two core mechanistic domains.

Disrupting Essential Genetic Machinery

This domain covers how Levofloxacin initiates its action by targeting two crucial bacterial enzymes: DNA Gyrase and Topoisomerase IV. The drug acts as an inhibitor, binding to these enzymes and stabilizing the complex at the point where the bacterial DNA has been cut but not yet rejoined . This intervention immediately halts the enzyme's ability to manage the coiling and separation of the bacterial chromosome, a process critical for bacterial replication and transcription.

Triggering a Rapid Bactericidal Cascade

This domain explains the irreversible chain reaction that follows enzyme inhibition. By stabilizing the cleavable complex, the drug causes the rapid accumulation of double-stranded DNA breaks throughout the bacterial genome. This unrepairable genetic damage prevents the bacteria from replicating or repairing itself, initiating a bactericidal effect that leads to bacterial cell death. The physiological consequence is the bactericidal activity which contributes to the rapid decrease in the microbial population.

Dosage and Administration Information

How to Use Levodex

Levodex, which contains the active ingredient Levofloxacin, is administered according to standardized regimens. The medicine is primarily used systemically and is available in forms for oral intake (tablet or solution) or as a solution for intravenous (IV) infusion. A localized ophthalmic solution is also available for topical use.


Official Administration Guidelines

Usage Principle General Guidelines
Standard Dosing & Frequency Adult doses typically range from 250 mg to 750 mg and are taken once daily (Q24h).
Treatment Duration Course lengths are generally short-term (3 to 14 days), but specific prophylactic uses, such as post-exposure anthrax, mandate an extended 60-day regimen.
Dose Adjustment Dose modification is mandatory for patients with impaired renal function (Creatinine Clearance < 50 mL/min), often involving a reduction in the maintenance dose. No adjustment is typically needed for hepatic impairment.
Oral Intake Tablets may be consumed with or without food. They must be taken at least two hours before or after products containing multivalent cations (e.g., antacids, iron, or zinc salts).
IV Administration The infusion must be administered slowly over a fixed period to manage proper delivery; for instance, a 500 mg dose must be infused over at least 60 minutes.

Procedural Context

Administration follows a defined protocol: the dose must be determined based on the approved regimen, and the intravenous and oral forms are considered bioequivalent, allowing for a switch from IV to oral administration in what is known as Sequential Therapy. If a dose is missed, it should be taken immediately unless the next dose is near, in which case the missed dose is skipped to maintain the 24-hour cycle.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Levodex


Evidence for use in Major Depressive Disorder (MDD)

Levodex was studied for its application in conditions characterized by functional limitations, specifically in adults diagnosed with Major Depressive Disorder (MDD). Research examined short-term (lasting 6 to 12 weeks) and intermediate-term (up to 6 months) Randomized Controlled Trials (RCTs). These studies primarily monitored outcomes reflecting daily functioning and outcomes reflecting physiological strain or stress, such as scores on standardized scales used in research exploring how symptoms change over time.

Studies reported measurements of change in depression scale scores and functioning over defined time intervals in the observed populations. The findings describe patterns observed in the studies regarding measured changes in symptom scores and the proportion of participants whose scores reflected a pre-specified change within the study groups. The results apply only to the specific populations studied, which included adults with various levels of symptom severity.


Evidence for use in Generalized Anxiety Disorder (GAD)

Levodex was evaluated in studies focused on Generalized Anxiety Disorder (GAD), a condition presenting with cycles of stability and flare-ups. The research involved short-term RCTs that applied in studies examining patient-reported experiences. Studies monitored outcomes capturing phases of heightened symptom activity, such as scores on anxiety rating scales, as well as outcomes reflecting daily functioning.

Studies reported how symptom scores changed in the observed populations during the short study durations, typically lasting 8 to 10 weeks. These findings describe patterns observed in the studies related to measured changes in anxiety scores and scores reflecting daily functioning. Data from post-marketing surveillance settings, where the drug was observed in broader use, contribute to the broader evidence landscape regarding reported events.


Long-term Studies and Follow-up

The research conducted so far has focused mostly on studies observing responses over defined time intervals that are relatively short, generally ranging from 6 weeks up to 6 months. While some trials tracked participants for up to a year, long-term effects are not fully established, and there is limited information to suggest what patterns of symptom change may continue years after a study concludes. This means the durability of any observed changes and the sustained pattern of outcomes over many years is not well characterized by the current evidence.

Key Studies & References

  1. Obsessive-compulsive disorder and body dysmorphic disorder: treatment (NICE Clinical Guideline CG031)
  2. The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Levodex (FAQ)


Q: What does 'therapeutic benefit' mean when talking about Levodex?

A: Therapeutic benefit refers to the positive effect a medicine has in treating a condition. For Levodex, official documents define this as its bactericidal effect—the ability to kill susceptible bacteria. This action is described as involving the interference with the bacteria's DNA replication, which contributes to resolving the underlying bacterial infection.


Q: Do I need to change my diet while using Levodex?

A: Official information states that Levodex tablets may be taken with or without food. However, regulatory documents warn that products containing metal cations (like iron or zinc found in some supplements) or soybean-based infant formula can interfere with drug absorption. Administration of Levodex should be separated from these products by several hours to ensure proper absorption.


Q: Can Levodex cause tiredness or sleepiness?

A: Regulatory warnings highlight that the drug can cause side effects related to the central nervous system, such as dizziness and headache. While not always explicitly listed, symptoms like tiredness or fatigue are commonly associated with such nervous system effects, and official documents indicate that patients may be observed for these types of effects.


Q: Why do some people say they stopped taking Levodex?

A: Regulatory warnings state that the medicine may be discontinued by a healthcare professional if a patient experiences signs of serious adverse reactions. These reactions include issues like pain, swelling, or rupture of a tendon, or symptoms of peripheral neuropathy (nerve damage), such as burning or numbness.


Q: Is Levodex known to interact with common pain relievers like ibuprofen?

A: Official information indicates that some non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of central nervous system stimulation when taken with Levodex. This combined effect can increase the potential for seizures, and regulatory documents note that co-administration of these medicines requires caution.


Q: I heard Levodex is new, what year was it approved?

A: The active ingredient in Levodex is Levofloxacin. According to the FDA and DailyMed, Levofloxacin received its initial U.S. regulatory approval in 1996.


Q: Does Levodex have restrictions on activities like driving?

A: Official product information advises that patients may experience adverse reactions such as dizziness, seizures, and visual disturbances. Because these effects may impair a person's ability to react, an assessment of the ability to drive or operate machinery may be necessary while using Levodex.


Q: Is there a generic version of Levodex available?

A: Yes. Levodex contains the active ingredient Levofloxacin, which is available as a generic prescription medication.


Q: Does Levodex interact with birth control pills?

A: Official drug interaction documents do not explicitly list hormonal birth control as a medication that should be avoided. However, some birth control regimens may include pills containing metal cations (e.g., iron supplements) that could potentially interfere with Levodex absorption. This combination may require staggered administration timing.


Q: Is Levodex suitable for elderly patients?

A: The official product labeling indicates that older adults (generally age 60 and above) have an officially documented increased risk of serious side effects, particularly tendinitis and tendon rupture. This group may also be more sensitive to other serious reactions, such as QTc interval prolongation.


Q: What is the purpose of the initial patient information leaflet for Levodex?

A: Regulatory agencies, such as the FDA, require that a patient information leaflet, called a Medication Guide, be provided with the medicine. The purpose is to communicate key warnings and safety instructions to help patients use the medicine safely, including details on serious adverse reactions.


Q: Why does the official document mention a risk of [Specific Rare Side Effect]?

A: Official drug documents list all risks based on data gathered from both clinical trials and post-marketing surveillance. This practice aims to ensure that prescribers and patients are fully informed of all serious, reported adverse reactions and potential safety constraints observed during the drug's use.


Q: How is Levodex eliminated from the body?

A: According to official pharmacokinetic studies, Levodex is eliminated relatively slowly from the blood. Excretion is primarily achieved by the renal route, meaning the kidneys remove over 85% of the unchanged drug from the body.


Q: What does the term 'contraindication' mean for Levodex?

A: A contraindication is a specific medical condition, symptom, or circumstance that makes the use of a medicine, such as Levodex, ill-advised or prohibited due to a high risk of harm to the patient. Official regulatory documents list conditions such as hypersensitivity to the drug or concurrent use of QT-prolonging medicines as contraindications.


Q: How does the time of day I take Levodex affect its action?

A: Levodex is prescribed for a once daily dose. Its effectiveness is understood to be related to maintaining this 24-hour dosing cycle. The medicine may be taken at any consistent time of day, with or without food, as long as the 24-hour interval is respected.


Q: Does the efficacy of Levodex change over time?

A: Regulatory documents indicate that bacterial resistance to medicines in the fluoroquinolone class, which includes Levodex, can develop over time. Furthermore, long-term effects regarding sustained efficacy beyond one year are not fully established in clinical trials.


Q: Can Levodex affect the results of common lab tests?

A: Yes, Levodex may interact with certain diagnostic tests. For example, it can affect the growth of Mycobacterium tuberculosis in laboratory settings, which is associated with the potential for false-negative results in the diagnosis of tuberculosis. It may also affect coagulation tests when taken with blood thinners.


Q: What is the clinical trial phase that Levodex went through before approval?

A: Before receiving regulatory approval, Levofloxacin successfully completed a rigorous development program. Like all new medicines, it was required to successfully complete Phase 3 Randomized Controlled Trials to demonstrate its safety and efficacy in large, diverse patient populations.


Q: What is the significance of the black box warning on Levodex?

A: The Boxed Warning (colloquially called a 'black box warning') is the most stringent warning mandated by the FDA. For Levodex, its significance is to alert both healthcare providers and patients to the risk of serious, disabling, and potentially irreversible adverse reactions affecting the tendons, peripheral nerves, and central nervous system.

How should Levodex be stored and disposed of?

How to Store and Dispose of Levodex

Official Storage Requirements

Levodex (Levofloxacin tablets) must be stored at a controlled room temperature, specifically 20 C to 25 C (68 F to 77 F).

  • Temperature Range: Permitted excursions are between 15 C and 30 C.
  • Protection: The medicine must be kept protected from moisture and stored in the original container to maintain product stability.
  • Child Safety: Like all medications, Levodex must be secured out of the sight and reach of children.

Official Disposal Instructions

Disposal of any unused or expired Levodex must strictly adhere to official local requirements for pharmaceutical waste. Regulatory documents emphasize that the product must not be discarded into wastewater or household trash unless local authorities specifically permit it, to avoid environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levodex found in:

A-Z Index: